Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Consortium to Develop MicroRNA-Based Drugs for Treatment of Head and Neck Cancer

By BiotechDaily International staff writers
Posted on 28 Nov 2013
Print article
A consortium of biotechnology companies and medical centers from The Netherlands, Germany, and Israel has been granted funding from the European Union’s FP7 program to develop a new class of highly selective targeted therapeutics for the treatment of head and neck cancer based on novel tumor-selective lethal micro RNAs (miRNAs).

Head and neck cancer is the sixth most common cancer worldwide, and since patients with this type of cancer often present with advanced stages of disease, the five-year survival rate is less than 60%.

miRNAs are snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. Considerable effort is going into development of clinical therapeutic applications for miRNAs.

The new project, which is known by the acronym MiRacle, brings together the biopharmaceutical companies InteRNA Technologies BV (Nijmegen, The Netherlands); Quiet Therapeutics (Ness Ziona, Israel); BioSpring (Frankfurt, Germany); OctoPlus (Leiden, The Netherlands); and LPT (Hamburg, German) and the Dutch medical center, VU University Medical Center (Amsterdam, The Netherlands).

The MiRacle consortium, which has been awarded an SME (small manufacturing entity) grant of about 1.2 million euros, will call upon its members for synthesis of biochemically active miRNAs, expertise in drug formulation for the specific delivery of therapeutic miRNA into humans, understanding of synthesis of complex drug formulations, preclinical testing, and conducting of toxicity tests that are required for RNA based drug registration.

Roel Schaapveld, CEO of InteRNA Technologies, said, “The unique tumor-selective lethal miRNAs identified display a very interesting biology and potential therapeutic effect that warrants further development towards the clinic. This FP7 grant exemplifies that with this consortium we have all the expertise in place to bring a tumor killing miRNA in a targeted and safe manner towards registration for first in human testing.”

“This FP7 grant enables the next step in the translation of the tumor-selective lethal microRNAs that we discovered,” said Dr. Ruud Brakenhof, professor of cancer genetics at VU University Medical Center.

Related Links:

InteRNA Technologies BV
Quiet Therapeutics
OctoPlus



Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A 3D nanofiber net formed by the supergelators to trap oil molecules (Photo courtesy of IBN at A*STAR / Institute of Bioengineering and Nanotechnology).

Effective Cleanup with Smart Material That Forms Oil-Trapping Net

Researchers have developed supergelators – an organic oil-scavenging material that rapidly forms a 3D net to trap oil molecules, gelatinizing into solidified masses that can be more easily removed from... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.